CSIMarket
 



Rigel Pharmaceuticals Inc  (RIGL)
Other Ticker:  
 
 



 

What are Rigel Pharmaceuticals Inc's Business Segments?



Rigel Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative drugs for the treatment of immune and hematologic disorders. The company's products and services are divided into several segments, including research and development, clinical trials, and commercialization.

Segment: Research and Development

Rigel Pharmaceuticals invests heavily in research and development to create new drugs that are highly effective in treating a variety of diseases. The company's research and development efforts are focused on several key areas, including the following:

1. Heme synthesis inhibitors: Rigel Pharmaceuticals is developing drugs that inhibit the production of heme, a substance that is essential for the survival of red blood cells. These drugs are being investigated as potential treatments for various hematologic disorders, including anemia and thalassemia.

2. Fostamatinib: Fostamatinib is an oral drug that inhibits the activity of spleen tyrosine kinase (SYK), an enzyme that is involved in immune system function. Rigel Pharmaceuticals is developing fostamatinib for the treatment of various autoimmune disorders, including rheumatoid arthritis and IgA nephropathy.

3. Other novel compounds: In addition to its work on heme synthesis inhibitors and fostamatinib, Rigel Pharmaceuticals is also developing other novel compounds that target specific proteins and pathways involved in immune and hematologic disorders.

Segment: Clinical Trials

Rigel Pharmaceuticals conducts clinical trials to test the safety and effectiveness of its drugs in humans. The company's clinical trial program is divided into several phases, including the following:

1. Phase I: In this initial phase, Rigel Pharmaceuticals tests its drugs in small groups of healthy volunteers to determine the drug's safety profile and the dosage range that can be given safely.

2. Phase II: In this phase, the company tests the drug in a larger group of patients with the disease or condition being targeted to determine its effectiveness and optimal dosage.

3. Phase III: In this final phase, Rigel Pharmaceuticals tests the drug in large groups of patients to confirm its effectiveness and to gather additional data on its safety and side effects.

Segment: Commercialization

Once Rigel Pharmaceuticals' drugs have passed the clinical trial phase, the company focuses on commercialization, which involves manufacturing, marketing, and distributing the drug. The company's commercialization efforts are divided into several key areas, including the following:

1. Manufacturing: Rigel Pharmaceuticals has a robust manufacturing process in place to ensure that its drugs are produced consistently and at a high level of quality.

2. Sales and marketing: The company has an experienced sales and marketing team in place to promote its drugs to healthcare providers and patients.

3. Distribution: Rigel Pharmaceuticals works with third-party distributors to ensure that its drugs are available to patients in need, both in the United States and internationally.
   

Rigel Pharmaceuticals Inc Tax Rate Companies within the Major Pharmaceutical Preparations Industry


Business Segments Q3
Revenues
(in millions $)
Q3
Income
(in millions $)
(Sep 30 2023)
%
(Profit Margin)
Total 28.13 -5.69 -

Growth rates by Segment Q3
Y/Y Revenue
%
(Sep 30 2023)
Q/Q Revenue
%
Q3
Y/Y Income
%
(Sep 30 2023)
Q/Q Income
%
Total 25.54 % 4.64 % - -

To get more information on Rigel Pharmaceuticals Inc's Total segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com